ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Brown on Idelalisib Plus Rituximab in CLL

Jennifer Brown, MD, PhD
Published: Sunday, Dec 08, 2013



Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the development of the novel PI3K-delta inhibitor idelalisib as a treatment for patients with chronic lymphocytic leukemia (CLL).

There are currently 3 large registration trials exploring idelalisib, Brown states. One of these trials, a phase III study combining idelalisib with rituximab for patients with previously treated CLL, was halted early due to a high-level of efficacy in an interim analysis conducted by an external Data Monitoring Committee.

The median progression-free survival (PFS) for patients treated with idelalisib plus rituximab has not yet been reached. For rituximab plus placebo, the median PFS was 5.5 months. At the 24-week analysis of the trial, the PFS rate was 93% compared to 46%, for idelalisib and placebo, respectively.

<<< View more from the 2013 ASH Annual Meeting



Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the development of the novel PI3K-delta inhibitor idelalisib as a treatment for patients with chronic lymphocytic leukemia (CLL).

There are currently 3 large registration trials exploring idelalisib, Brown states. One of these trials, a phase III study combining idelalisib with rituximab for patients with previously treated CLL, was halted early due to a high-level of efficacy in an interim analysis conducted by an external Data Monitoring Committee.

The median progression-free survival (PFS) for patients treated with idelalisib plus rituximab has not yet been reached. For rituximab plus placebo, the median PFS was 5.5 months. At the 24-week analysis of the trial, the PFS rate was 93% compared to 46%, for idelalisib and placebo, respectively.

<<< View more from the 2013 ASH Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x